Coherus reports 75% confirmed response rate for Tagmokitug combo in first-line esophageal squamous cell carcinoma

Coherus reported a 75% confirmed response rate for its Tagmokitug combination in first-line esophageal squamous cell carcinoma, based on interim Phase 1b data in 8 evaluable patients.

Detected & updated continuously · Source: Nebula